In today’s briefing:
- Lucror Analytics – Morning Views Asia
- Multi Bintang Indonesia (MLBI IJ) Q3 FY25: Resilient >9% Yield Intact, But No Inflection In Demand
- Primer: Bukit Uluwatu Villa (BUVA IJ) – Nov 2025

Lucror Analytics – Morning Views Asia
- In today’s Morning Views publication we comment on developments of the following high yield issuers: Medco Energi
- UST yields climbed 3-4 bps across the curve yesterday, amid heightened corporate supply after Alphabet Inc issued USD 25 bn of USD- and EUR-denominated bonds. The yield on the 2Y and 10Y UST rose 3 bps each to 3.61% and 4.11%, respectively.
- Equities climbed, supported by tech stocks after Amazon’s Cloud unit inked a USD 38 bn deal with OpenAI. The S&P 500 edged up 0.2% to 6,852, while the Nasdaq grew 0.5% to 23,835.
Multi Bintang Indonesia (MLBI IJ) Q3 FY25: Resilient >9% Yield Intact, But No Inflection In Demand
- Multi Bintang Indonesia (MLBI IJ) reported Q3FY25 YoY revenue/profit declines of 4.3%/5.8%. 9MFY25 revenues/profits were +2%/-5% YoY, due to a slight decrease in margins.
- After a strong recovery in demand of 10% YoY in Q2, demand in Q3 was subdued at -4.3% YoY despite more substantial tourism numbers (10% YoY in Q3FY25, 12% Ytd)
- The stock trades at 10.7x FY25 PE, offers a 9.4% dividend yield, is net cash, and has a substantial ROCE of >70%.
Primer: Bukit Uluwatu Villa (BUVA IJ) – Nov 2025
- Poised for a Cyclical Upswing: As a pure-play operator of luxury villas and hotels in Bali, BUVA is a direct beneficiary of the robust recovery and positive outlook for Indonesian tourism. International arrivals are projected to continue growing, driving demand for high-end accommodation.
- Operational Turnaround Amid Financial Volatility: The company has demonstrated a significant revenue recovery post-pandemic, with a 3-year revenue CAGR of 79.5%. However, profitability remains volatile, as evidenced by significant net losses in 2022 and certain quarters of 2023/2024, highlighting operational gearing and sensitivity to occupancy rates.
- Stretched Valuation and No Yield: The stock trades at a premium valuation with a P/E ratio of 141.3x. This expensive multiple, combined with a long-term history of negative market cap growth and a consistent no-dividend policy, suggests the market has priced in a significant portion of the anticipated recovery.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.
